Figure 2.
Time to first event of cardiac failure (CF) and survival analyses in the ASPIRE and ENDEAVOR trials. (A) Time to first event of grade ≥3 CF and progression or death in the ASPIRE (A) and ENDEAVOR (C) trials. Time to first event of grade ≥3 CF and mortality in the ASPIRE (B) and ENDEAVOR (D) trials. The x-axis shows months since first dose for grade ≥3 CF AEs and months since randomization for PFS or OS.